A meta-analysis of clinical benefit rates for fulvestrant 500 mg versus alternative therapies for treatment of postmenopausal, estrogen receptor-positive advanced breast cancer

被引：1
|
作者：
Robertson, J. F. R.
Zefei, J.
Di Leo, A.
Ohno, S.
Pritchard, K. I.
Ellis, M.
Bradbury, I.
Campbell, C.
机构：
[1] Univ Nottingham, Div Breast Surg, Nottingham NG7 2RD, England
[2] Chinese Peoples Liberat Army, Hosp 307, Beijing, Peoples R China
[3] Hosp Prato, Sandro Pitigliani Med Oncol Unit, Prato, Italy
[4] Canc Inst Hosp, Breast Oncol Ctr, Tokyo, Japan
[5] Sunnybrook Odette Canc Ctr, Toronto, ON, Canada
[6] Univ Toronto, Toronto, ON, Canada
[7] Baylor Coll Med, Houston, TX 77030 USA
[8] Frontier Sci, Kingussie, Inverness, Scotland
来源：
CANCER RESEARCH | 2016年 / 76卷
关键词：
D O I：
10.1158/1538-7445.SABCS15-P5-14-01
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P5-14-01
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Factors associated with prolonged time to treatment failure with fulvestrant 500mg in patients with postmenopausal estrogen receptor-positive advanced/metastatic breast cancer (JBCRG-C06; Safari): A subgroup analysis
    Kawaguchi, H.
    Aogi, K.
    Masuda, N.
    Nakayama, T.
    Ito, Y.
    Ohtani, S.
    Sato, N.
    Takano, T.
    Saji, S.
    Tokunaga, E.
    Hasegawa, Y.
    Hattori, M.
    Fujisawa, T.
    Morita, S.
    Yamashita, H.
    Yamashita, T.
    Yamamoto, Y.
    Yotsumoto, D.
    Toi, M.
    Ohno, S.
    ANNALS OF ONCOLOGY, 2017, 28
  • [22] Fulvestrant 500 mg vs 250 mg: first results from NEWEST, a randomized, phase II neoadjuvant trial in postmenopausal women with locally advanced, estrogen receptor-positive breast cancer
    Kuler, I
    Hegg, R.
    Singer, C. F.
    Badwe, R.
    Lowe, E.
    BREAST CANCER RESEARCH AND TREATMENT, 2007, 106 : S7 - S7
  • [23] Fulvestrant 500 mg vs 250 mg: first results from NEWEST, a randomized, phase II neoadjuvant trial in postmenopausal women with locally advanced, estrogen receptor-positive breast cancer
    Kuter, I.
    Hegg, R.
    Singer, C. F.
    Badwe, R.
    Lowe, E.
    BREAST CANCER RESEARCH AND TREATMENT, 2008, 109 (03) : 589 - 590
  • [24] Cost-Effectiveness Analysis of Fulvestrant 500 mg in Endocrine Therapy-Naïve Postmenopausal Women with Hormone Receptor-Positive Advanced Breast Cancer in the UK
    Claire Telford
    Evelina Bertranou
    Samuel Large
    Hilary Phelps
    Mattias Ekman
    Christopher Livings
    PharmacoEconomics - Open, 2019, 3 : 559 - 570
  • [25] Safety and tolerability of fulvestrant high-dose (500 mg) in postmenopausal women with hormone receptor positive advanced breast cancer
    Gottschalk, N.
    Kuter, I.
    Robertson, J. F.
    Ellis, M. J.
    Lindeman, J.
    Schrader, I.
    Gerber, B.
    Costa, S. D.
    Harbeck, N.
    EJC SUPPLEMENTS, 2009, 7 (02): : 284 - 285
  • [26] Therapies for the Treatment of Advanced/Metastatic Estrogen Receptor-Positive Breast Cancer: Current Situation and Future Directions
    Rej, Rohan Kalyan
    Roy, Joyeeta
    Allu, Srinivasa Rao
    CANCERS, 2024, 16 (03)
  • [27] A meta-analysis of anastrozole in combination with fulvestrant in the first line treatment of hormone receptor positive advanced breast cancer
    Pui San Tan
    Haaland, Benjamin
    Montero, Alberto J.
    Lopes, Gilberto
    BREAST CANCER RESEARCH AND TREATMENT, 2013, 138 (03) : 961 - 965
  • [28] A meta-analysis of anastrozole in combination with fulvestrant in the first line treatment of hormone receptor positive advanced breast cancer
    Pui San Tan
    Benjamin Haaland
    Alberto J. Montero
    Gilberto Lopes
    Breast Cancer Research and Treatment, 2013, 138 : 961 - 965
  • [29] Progression-Free Survival with Fulvestrant 500 mg and Alternative Endocrine Therapies as Second-Line Treatment for Advanced Breast Cancer: A Network Meta-Analysis with Parametric Survival Models
    Cope, Shannon
    Ouwens, Mario J. N. M.
    Jansen, Jeroen P.
    Schmid, Peter
    VALUE IN HEALTH, 2013, 16 (02) : 403 - 417
  • [30] A comparison of fulvestrant plus a targeted agent with fulvestrant alone in hormone receptor-positive advanced breast cancer that progressed on prior endocrine therapy: a meta-analysis
    Xu, Liang
    Yan, Ningning
    Li, Zhihua
    Luo, Lihua
    Wu, Xiaobo
    Liu, Qiuming
    Xu, Yingchun
    Cao, Yali
    ONCOTARGETS AND THERAPY, 2018, 11 : 8389 - 8398
12345